What does license agreement — net revenue mean?

This metric represents the total net revenue generated from licensing intellectual property, patents, or proprietary technology to third-party partners. It reflects the company's ability to monetize its research and development pipeline through non-core commercialization channels. Fluctuations in this revenue stream indicate the timing of milestone achievements, royalty payments, or the strategic divestiture of product rights.

Amneal Pharmaceuticals, Inc. (AMRX) License agreement — Net revenue

Screener

Other product segments

Subtotal dosage forms

$482.3M+11.8%

Oral solid

$175.17M-1.7%

Subtotal therapeutic classes

$149.3M+17.1%

Central nervous system

$95.34M+14.3%

Distribution

$86.93M-12.8%

Other dosage forms

$81.59M+19.7%

Transdermal

$67.04M+64.7%

Auto-Injector

$62.21M-6.6%

Injectable

$56.78M+63.9%

Government label

$50.21M+10.5%

Hormonal / allergy

$42.1M+18.9%

Biosimilar

$29.13M+15.4%

Institutional

$12.11M+19.5%

Other therapeutic classes

$11.85M+36.2%

Oral liquid

$10.37M-42.0%

International

$7.61M+300%

Similar metrics at other companies

IBPNet revenue, Installation — Net revenue

$710.7M-0.7%

MQPlatform services revenue, net — Net revenue

$156.23M+18.5%

VOther revenue — Net revenue

$1.5B+45.5%

VService revenue — Net revenue

$4.92B+13.7%

CVCODelivery, setup and other revenues — Net revenue

$23.21M-15.9%

MQOther services revenue — Net revenue

$9.57M+32.8%

Other financials

Income statement

See full

Revenue$796.2M+9.9%

Gross profit$334.5M+16.9%

Operating income$129.8M+16.5%

Net income$57.7M+157%

EPS (diluted)$0.18+157%

Balance sheet

See full

Cash & equivalents$127.6M+78.4%

Total debt$2.6B+18.0%

Total equity$33.0M+129%

Total assets$3.8B+10.3%

Cash flow

See full

Operating cash flow-$21.2M-125%

CapEx$30.7M+34.5%

Free cash flow-$51.9M-185%

Valuation

See full

Market cap$5.89B+129%

Enterprise value$8.34B+77.4%

P/E37.5×-726×

P/S1.9×+1.0×

Profitability

See full

Gross margin39.3%+1.7pp

Operating margin14.6%+1.4pp

Net margin5%+4.9pp

FCF margin4.1%-5.8pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity77.8×—

Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:19 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001723128-26-000031

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Net revenue	$796,197	$724,508	$1,518,716	$1,419,928
Cost of goods sold	461,689	438,255	864,095	877,784
Gross profit	334,508	286,253	654,621	542,144
Selling, general and administrative	148,722	124,266	287,582	242,554
Research and development	39,017	47,964	77,400	88,004
Intellectual property legal development expenses	2,087	2,017	3,629	3,784
Acquisition costs	7,600	—	12,753	—
Restructuring and other charges	554	1,024	1,204	1,595

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s license agreement — net revenue?: Amneal Pharmaceuticals, Inc. (AMRX) reported license agreement — net revenue of $0 in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s license agreement — net revenue changed year-over-year?: Amneal Pharmaceuticals, Inc.'s license agreement — net revenue decreased by 100.0% year-over-year, from $500K to $0.
What does license agreement — net revenue mean?: This metric represents the total net revenue generated from licensing intellectual property, patents, or proprietary technology to third-party partners. It reflects the company's ability to monetize its research and development pipeline through non-core commercialization channels. Fluctuations in this revenue stream indicate the timing of milestone achievements, royalty payments, or the strategic divestiture of product rights.